




## Active substances set

Search phrase: brexucabtagene autoleucel

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.



	Acute lymphoblastic leukaemia Brexucabtagene	
Brexucabtagene autoleucel is indicated for the treatment of adult patients		V
autoleucel	26 years of age and above with relapsed or refractory B-	
	cell precursor acute lymphoblastic leukaemia (ALL).	$\checkmark$

FULL REIMBURSEMENT ESMO